NPNatalie Prochazkova

Natalie Prochazkova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalie Prochazkova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Imaging in a Mouse Model of Focal Cortical Dysplasia Reveals Lesion Expansion and Loss of Pre-Discharge Neuronal Recruitment

    by Monika ŘehořOvá, Jana Thao Rozlivková, Jana Populová, Natálie Procházková, Carl Václav Lím Olson, Niki Shariati, Jan Kudláček, PřEmysl Jiruška, OndřEj Novák

    Objective: Focal cortical dysplasia type II (FCD II) is a leading cause of drug-resistant focal epilepsy, yet how its lesional circuits behave and change over time in vivo has not been directly observed. Methods: We used a mouse model of FCD II carrying the patient-derived gain-of-function mTOR p.L2427P variant introduced by in utero electroporation. Through a chronic cranial window over the lesion, we performed repeated in vivo two-photon calcium imaging of identified dysmorphic neurons, pyramidal cells, and VIP interneurons at defined time points, combined with video-EEG monitoring, to determine seizure status and relate cellular activity to interictal discharges. Results: The lesion was not static in adulthood. Dysplastic cortex expanded progressively. This expansion occurred without the tenascin R/C accumulation reported in human FCD II, and was partly explained by continued somatic growth of dysmorphic neurons. Dysmorphic neurons were generally hypoactive; in seizing mice, both dysmorphic and pyramidal cell activity progressively declined, whereas VIP interneuron activity increased slightly in non-seizing animals. In non-seizing lesional cortex, neurons were reliably recruited immediately before interictal discharges. By late disease stages, pre-discharge recruitment had weakened to the point that lesional layer 2/3 neurons were no more active before discharges than expected by chance. Significance: These findings recast FCD II as a lesion that continues to remodel structurally and functionally throughout adulthood, and does so most markedly in animals with seizures. Growth, a cell-type-specific shift in spontaneous activity, and a progressive loss of the lesion’s temporal lead over interictal discharges together suggest that FCD II is a dynamically evolving lesion whose relationship to epileptiform activity changes over time. If the lesion progressively loses its generative role, the window in which removing it can arrest the disease is finite, consistent with clinical evidence favoring earlier surgery. Key points: The same neurons inside an FCD II lesion were imaged in vivo across epileptogenesis Dysplastic cortex expanded over weeks, tending to be larger in seizing mice Expansion coincided with dysmorphic neuron growth without bulk tenascin R/C increase In seizing mice, dysmorphic and pyramidal neurons became progressively less active Pre-discharge neuronal recruitment in non-seizing mice was absent in seizing mice


  • Open Access

    High-frequency oscillations reveal progressive recruitment of remote cortex into the epileptic network in a mouse model of focal cortical dysplasia type II

    by Nedime Karakullukcu, Michal Scheibel, Natalie Prochazkova, Bohdana Hruskova, Michaela Kralikova, Ondrej Novak, Helena Pivonkova, Jan Kudlacek, Premysl Jiruska

    Interictal epileptiform discharges (IEDs) and pathological high-frequency oscillations - (HFOs) are established biomarkers of epileptogenic tissue, but how their spatiotemporal evolution reflects epileptic network reorganization in neocortical epilepsy remains unclear. We investigated longitudinal IED and HFO dynamics throughout epileptogenesis and chronic epilepsy in a mouse model of focal cortical dysplasia type II (FCD II). Long-term bilateral cortical recordings were obtained before and after spontaneous seizure onset. IEDs and HFOs (gamma, ripples, and fast ripples) were quantified in the dysplastic lesion and contralateral cortex during pre-epileptic, early, and late epileptic stages. The dysplastic lesion remained the principal seizure onset zone throughout disease progression and showed stable HFO activity after epilepsy onset. In contrast, the contralateral cortex exhibited progressive increases in IEDs and HFOs, demonstrating continuous recruitment into the epileptic network. Fast ripples were the earliest marker of this process, emerging within the first week after the first seizure and preceding increases in ripples, gamma, and IEDs. Propagation analysis showed that this contralateral increase was driven by independently generated HFOs rather than propagation from the lesion, indicating emergence of autonomous epileptogenic activity outside the primary focus. Spatiotemporal HFO analysis thus captures dynamic epileptic network remodeling beyond epileptogenic lesion. Fast ripples may serve as an early signature of network expansion and epileptogenicity emerging outside the primary lesion. Widespread structural and connectivity abnormalities extending beyond the lesion, combined with intense recurrent epileptic activity, may underlie the high endogenous epileptogenicity of FCD II, enabling small dysplastic lesions to recruit extensive neuronal networks across both hemispheres.

  • Open Access

    Chronic In Vivo Imaging of a Focal Cortical Dysplasia Mouse Model Reveals Progressive Neuronal Loss with No Senolytic or Antiseizure Efficacy Following Dasatinib–Quercetin Treatment

    by C.V.L. Olson, N. Shariati, N. Procházková, K. Čížek, M. ŘehořOvá, J. Populová, J.T. Rozlivková, S. Wang, B. Ricketts, B. Kučerová, et al.

    Summary: Objective: Focal cortical dysplasia (FCD) type II is a common cause of pediatric drug-resistant epilepsy with no disease-modifying treatment. It arises from somatic mutations in the mTOR pathway that produce a mosaic population of mTOR-hyperactive dysmorphic neurons (DNs) with a senescence phenotype. A recent report showed that oral dasatinib– quercetin (DQ), both putative senolytics, selectively eliminates these neurons and abolishes seizures in an Mtor p.S2215F model. However, this has not been tested in a second FCD model and neuron loss was shown only by cross-sectional histology. Methods: Using chronic cranial windows and longitudinal in vivo two-photon imaging, we tracked genetically labeled neurons over eight weeks. In a mosaic MTOR p.L2427P FCD model on a C57BL/6J background, we combined imaging with continuous video-EEG, immunohistochemistry (IHC), and LC–MS/MS pharmacokinetics in 47 mice. Seizure and pharmacokinetic sampling were extended to a smaller Swiss/CD1 cohort, the strain used previously. Results: Imaging revealed progressive loss of mTOR mut (16.7%) and non-mTOR mut (13.1%) neurons, with minimal loss in unmatched non-FCD controls. In IHC, lesions contained β-galactosidase-positive (B-Gal + ) cells, but oral DQ showed no evidence of eliminating DNs or reducing seizure frequency, duration, or burden; seizures also persisted in CD1 mice. B-Gal + cells tended to be less dense after DQ, but not significantly after correction. These data are more consistent with a senomorphic than a senolytic effect. Brain dasatinib (median 8.5 nM) exceeded its Src/ABL IC 50 , whereas quercetin (median 12 nM) was nearly two orders of magnitude below its BCL-XL affinity. Significance: Longitudinal tracking of single neurons shows progressive loss of labeled neurons in an FCD model, whereas the reported senolytic and antiseizure effects of DQ were not reproduced. DQ should not be assumed to act as a senolytic across FCD models, strains, or MTOR variants. Dependence on strain, mutation, or brain exposure bears on clinical translation. Key Points Longitudinal in vivo two-photon imaging showed progressive loss of mTOR-mutant neurons in an FCD type II mouse model Oral dasatinib–quercetin treatment did not eliminate dysmorphic neurons or reduce seizures in C57BL/6J mice; seizures persisted in CD1 mice Dasatinib–quercetin did not eliminate neurons or abolish seizures in an MTOR p.L2427P FCD model, so its efficacy may not generalize

  • Open Access

    SEIZURE OCCURRENCE IN FCD TYPE II IS PREDICTED BY LESION POSITION AND LINKED TO CYTOARCHITECTURAL ALTERATIONS

    by N Procházková, Cvl Olson, N Shariati, Mt Rozlivková, J Populová, M ŘehořOvá, J Kudláček, P Jiruška, O Novák

    Focal cortical dysplasia (FCD) is a common malformation of cortical development and a major cause of early-onset, drug-resistant epilepsy. FCD type II is defined by abnormal lamination, altered cellular composition, and pathological cells, notably dysmorphic neurons (DNs) and balloon cells. DNs are thought to drive epileptogenicity through both cell-autonomous and non-cell-autonomous mechanisms, the latter including not only aberrant connectivity but also indirect modulation of excitability in local cell populations. We performed a multiscale structural and morphological analysis to elucidate the basis of FCD epileptogenicity and the impact of somatic mTOR mutations during brain development. Using a mouse model of FCD type II, we show that lesions in frontal and motor cortical regions are the strongest predictors of spontaneous seizure occurrence. This localization-dependent epileptogenicity offers an experimental explanation for the higher clinical epileptogenicity of frontal FCDs and suggests that posterior lesions may remain silent—an open question in human pathology. In our model, FCD tissue displayed considerable expansion, with cortical thickness up to ∼20% in seizure-bearing animals. This expansion coincided with an overall ∼40% reduction in neuronal density, consistent with tissue hypertrophy. DN density did not differ between seizure and non-seizure animals, challenging the notion that higher DN load directly predicts epileptogenesis. At the microscopic level, we describe DN axonal pathologies, including giant varicosities. In the cortex, these appeared as vesicle-filled boutons, whereas along callosal axons they were frequent but largely empty. Bouton density was markedly reduced in FCD cortex. Together, these findings leave the net synaptic effect of dysmorphic neurons unresolved, challenging the assumption that axonal hypertrophy translates into increased excitatory drive. While morphological abnormalities in FCD type II are well documented, their functional consequences remain incompletely understood. Here, we used macro- and microscopic structural features of FCDII to assess seizure susceptibility, providing new insights into epileptogenesis.